The EDC is live today — see what ships now
All studies
NCT07377006From ClinicalTrials.govRecruiting

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Efforts to Enhance Germline Genetic Testing at Lyndon B. Johnson Hospital

  • Prostate Carcinoma

At a glance

Phase
Phase not stated
Study type
Interventional
Sponsor
M.D. Anderson Cancer Center
Enrolment target
108
Started
2 February 2026
Main results due
31 May 2030
Study sites
1
Registry updated
25 September 2026

Can you take part?

  • Aged 18 years and over.
  • Men only.
  • You need the condition being studied — healthy volunteers are not accepted.

These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital
* Were recommended for germline genetic testing by their oncology provider
* Can provide informed consent
* Can communicate in English or Spanish

Exclusion Criteria:

* Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition

What this study is about

In the sponsor’s own words, from the registry.

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Study sites(1)

  • M D Anderson Cancer Center

    Houston, Texas, United States

    Recruiting

Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.

Source: ClinicalTrials.gov record NCT07377006. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Not the right study?

Answer three questions and see the studies recruiting near you, in plain language.

Find a study for me
Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer | Trialion